Your browser doesn't support javascript.
loading
Clinical trials with reno-vascular end points in patients with diabetes: Changing the scenario over the past 20 years.
Block, Tomasz J; Cooper, Mark E.
Affiliation
  • Block TJ; Department of Diabetes, Central Clinical School, Monash University, Melbourne, VIC, Australia.
  • Cooper ME; Department of Diabetes, Central Clinical School, Monash University, Melbourne, VIC, Australia. Electronic address: Mark.Cooper@monash.edu.
Presse Med ; 52(1): 104178, 2023 Mar.
Article in En | MEDLINE | ID: mdl-37783423
Major clinical advances over the last 20 years in the area of diabetic kidney disease (DKD) have been confirmed in large seminal clinical trials. These findings add to the previously identified benefits resulting from intensive glucose and blood pressure control therapies. Furthermore, newer glucose lowering treatments such as SGLT2 inhibitors and GLP-1 agonists appear very promising and are likely to transform the management and outlook of DKD over the next decade. In addition, novel mineralocorticoid receptor antagonists and a recently reported trial with an endothelin receptor blocker also have the potential to change clinical practice.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Diabetes Mellitus, Type 2 / Diabetic Nephropathies / Sodium-Glucose Transporter 2 Inhibitors Type of study: Prognostic_studies Limits: Humans Language: En Journal: Presse Med Year: 2023 Document type: Article Affiliation country: Australia Country of publication: France

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Diabetes Mellitus, Type 2 / Diabetic Nephropathies / Sodium-Glucose Transporter 2 Inhibitors Type of study: Prognostic_studies Limits: Humans Language: En Journal: Presse Med Year: 2023 Document type: Article Affiliation country: Australia Country of publication: France